Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001601830-24-000224
Filing Date
2024-11-26
Accepted
2024-11-26 16:48:25
Documents
14
Period of Report
2024-08-08
Items
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K/A rxrx-20240808.htm   iXBRL 8-K/A 21727
  Complete submission text file 0001601830-24-000224.txt   156135

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rxrx-20240808.xsd EX-101.SCH 2042
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rxrx-20240808_def.xml EX-101.DEF 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rxrx-20240808_lab.xml EX-101.LAB 23477
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rxrx-20240808_pre.xml EX-101.PRE 14135
16 EXTRACTED XBRL INSTANCE DOCUMENT rxrx-20240808_htm.xml XML 2748
Mailing Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101
Business Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203
RECURSION PHARMACEUTICALS, INC. (Filer) CIK: 0001601830 (see all company filings)

EIN.: 464099738 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40323 | Film No.: 241504856
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)